Amarin Corporation Plc · NASDAQ:AMRN
Amarin — Q3 2026 Earnings Presentation
17 slides from Amarin's earnings presentation, October 2026
Slide 1: At the Heart of Cardiovascular Risk Reduction
AT THE HEART OF CARDIOVASCULAR PLACEHOLDER FOR HERO IMAGE RISK REDUCTION Replace with licensed photography COMPANY OVERVIEW NASDAQ: AMRN | OCTOBER 2026 AMARIN LOGO 1
Slide 2: Forward Looking Statements & Disclaimer
Forward Looking Statements & Disclaimer This presentation contains forward-looking statements, such as those relating to the commercial potential of VASCEPA® (icosapent ethyl) (VAZKEPA® in Europe and in other territories), clinical and regulatory efforts and timelines, potential regulatory and prici
Slide 3: A Message from our President & CEO
A Message from our President & CEO “Our results in the third quarter demonstrate the continued trajectory in our operational, financial, and strategic transformation, underscoring the progress we are making to strengthen our business, expand the value of our VASCEPA®/VAZKEPA® (icosapent ethyl, or IP
Slide 4: VASCEPA / VAZKEPA (icosapent ethyl or IPE)
VASCEPA® / VAZKEPA® (icosapent ethyl or IPE) 25 The first and only FDA-approved oral medication to reduce cardiovascular (CV) risk when added to recommended statin therapy % Clinically Validated and Widely Prescribed ~32M 279K+ U.S. prescriptions U.S. prescribers written since 2013 RELATIVE RISK RED
Slide 5: Delivering Impactful, Cost-Effective Outcomes
VASCEPA® / VAZKEPA®: Delivering Impactful, Cost-Effective Outcomes USA ICER Institute & JAMA publication findings suggest that treatment with IPE may be cost-effective among patients with high cardiovascular risk whose triglyceride levels remain high despite statin therapy. 9,10 UK’s NICE recommende
Slide 6: Amarin's Evolution
1 From Therapeutic Innovation to Strategic Reset: A Clearer Path to Long-Term Growth Amarin’s Evolution INITIAL INDICATION APPROVED IN THE U.S 2012 VASCEPA® receives FDA clearance as an adjunct to diet to reduce triglyceride levels in adult patients with severe hypertriglyceridemia. Sales commenced
Slide 7: Reshaping Amarin: Building A More Durable, Capital-efficient Business
1 Reshaping Amarin: Building A More Durable, Capital-efficient Business We restructured the business model to adapt to today's realities and position Amarin for long-term success. 2013-2024 2024-2025 2026 + LEGACY MODEL ACTIONS TAKEN AMARIN TODAY Cost-efficient international business Significant inv
Slide 8: Transformation has Created the Foundation for Our Next Phase of Growth
Transformation has Created the Foundation for Our Next Phase of Growth Global Commercial Strategy Performing as Planned (All $ in MMs) Cash Flow from Cash, Equivalents, and Fully partnered international business model with multiple long- Operations Short-Term Investments duration revenue streams i
Slide 9: Our International Business: Addressing a Global Market Through Established Partners
Our International Business: Addressing a Global Market Through a Syndicate of Established Partners CANADA EUROPE Commercialization efforts New exclusive license & supply progressing agreement CHINA CVRR approval secured; Focus on Private Pay Market SOUTH KOREA AND 7 ASEAN South Korea and Singapore r
Slide 10: Recordati Partnership Advancing VAZKEPA's European Growth Opportunity
Recordati Partnership Advancing VAZKEPA’s European Growth Opportunity 12 KEY EUROPEAN MARKETS Commercialized & reimbursed within Recordati’s licensed territory European Commercial Footprint Sweden Country Reimbursement Launch Finland 1. Sweden March 2022 March 2022 Strong momentum 68% 2. Finland Oct
Slide 11: Our International Business: Partner-Led Growth Across Established and Emerging Markets
Our International Business: Partner-Led Growth Across Established and Emerging Markets INTERNATIONAL PARTNERSHIPS - CURRENT PHASES Strong Growth Across Commercial Markets VASCEPA® / VAZKEPA® In-Market Demand MENA CANADA +55% EUROPE AUSTRALIA CHINA ISRAEL +68% +181% +75% +92% +63% +13% YTD in-market
Slide 12: Our U.S. Business: VASCEPA Remains U.S. Market Leader
Our U.S. Business: VASCEPA® Remains U.S. Market Leader Across All Available IPE Products Enduring brand strength, differentiated clinical evidence, and continued confidence among prescribers and patients • Proven efficacy in cardiovascular risk reduction • Branded prescription growth reflects contin
Slide 13: Our Financials: Executing a More Efficient Operating Model
Our Financials: Executing a More Efficient Operating Model to Support Future Global Growth Key Takeaways: Operating Results: ($ in M) Q3 26 Q3 25 Change Q3 2026 highlighted by profitable results, lower Product Net Revenue $36.9 $48.6 (24)% operating expenses, cash flow from operations, U.S. Product
Slide 14: Investment Thesis: A Company That Has Already Transformed
Investment Thesis: A Company That Has Already Transformed The business has been transformed: A leaner operating model has materially reduced the cost base, strengthened the balance sheet, and established a path to sustainable cash generation, providing flexibility to fund strategic priorities whil
Slide 15: Amarin Key Takeaways
Amarin Key Takeaways HEALTHY FINANCIALS UNTAPPED POTENTIAL PRODUCT POWER STRONG SCIENCE MEDICAL ENDORSEMENT Cash Flow ~640M >279K 3 500+ PEOPLE LIVING WITH CVD, EXPECT TO BE CASH FLOW MAKING IT THE LEADING CAUSE U.S. PRESCRIBERS SUCCESSFUL PHASE 3 SCIENTIFIC PUBLICATIONS POSITIVE FOR FULL YEAR 2026
Slide 16: Glossary of Select Terms
Glossary of Select Terms VASCEPA / VAZKEPA • The first and only FDA-approved medication to lower CV risk in addition to other medications, such as statins, in patients with high triglycerides (≥150 mg/dL) and heart disease or diabetes with other CV risk factors. • Marketed as VASCEPA in the United S
Slide 17: References
References 1. REDUCE-IT® study N Engl J Med. 2019; 380 (1): 11-22. 2. In adults on maximally tolerated statins with TG> 150 mg/dL and established CVD or diabetes and ≥ 2 CVD risk factors. 3. In a clinical study, patients treated with VASCEPA and a statin had fewer cardiovascular (CV) events (17.2%)